A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
Public ClinicalTrials.gov record NCT01311661. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the Respimat® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma
Study identification
- NCT ID
- NCT01311661
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Interventions
- Olodaterol high daily dose once daily and placebo Drug
- Olodaterol low daily dose twice daily Drug
- Olodaterol medium daily dose once daily and placebo Drug
- Olodaterol medium daily dose twice daily Drug
- Placebo twice daily Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2011
- Primary completion
- Nov 30, 2011
- Completion
- Not listed
- Last update posted
- Apr 30, 2014
Started 2011
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1222.29.11006 Boehringer Ingelheim Investigational Site | Huntington Beach | California | — | — |
| 1222.29.11001 Boehringer Ingelheim Investigational Site | Centennial | Colorado | — | — |
| 1222.29.11012 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1222.29.11002 Boehringer Ingelheim Investigational Site | Overland Park | Kansas | — | — |
| 1222.29.11004 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1222.29.11011 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1222.29.11009 Boehringer Ingelheim Investigational Site | Skillman | New Jersey | — | — |
| 1222.29.11003 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1222.29.11008 Boehringer Ingelheim Investigational Site | Canton | Ohio | — | — |
| 1222.29.11007 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1222.29.11005 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1222.29.11010 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01311661, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2014 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01311661 live on ClinicalTrials.gov.